Oncology
|
Nexavar Significantly Improves Overall Survival By 47 Percent In Asia Pacific Liver Cancer Study
medicalnewstoday.com 5 hrs ago 5 related
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC),...
Ning Wong Of Fox Chase Cancer Center Receives ASCO Cancer Foundation Career Development Award
medicalnewstoday.com 1 hr ago 2 related
The American Society of Clinical Oncology Cancer Foundation has selected Yu-Ning Wong, M.D., M.S.C.E., of Fox Chase Cancer Center, as one of 13 clinicians to receive a 2008 Career Development Award. Career Development Awards are presented to physicians in their second, third or fourth year as...
New Treatment Implications For Ovarian Cancer Unveiled
medicalnewstoday.com 5 hrs ago 1 related
New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15,000 lives nationwide this year, with 480 in New Jersey.
Cancer Research Group Releases Data
redorbit.com 21 hrs ago 5 related
Studies of drugs that may stop the spread of many cancers -- vaccines for brain tumors, treatments that prevent bone metastases, vitamins that may improve the chances of breast cancer patients -- will be examined by some 30,000 oncologists and scientists at the world's biggest cancer-research...
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
redorbit.com 21 hrs ago 3 related
Posted on: Friday, 16 May 2008, 12:00 CDT SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 and predict response...
Adding epratuzumab to standard therapy
brightsurf.com 22 hrs ago 6 related
Study to be presented at the American Society of Clinical Oncology annual meeting ROCHESTER, Minn. -- Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer...
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
brightsurf.com 22 hrs ago 4 related
Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of...
ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study (PR...
yahoo.com 22 hrs ago 3 related
Friday May 16, 6:00 am ET - News ) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disorders and administration site conditions when compared to Navelbine® (p=0.014). In addition, in post hoc analyses,...
Biotech Stocks: Drug stocks mixed, Medarex gains on drug update
marketwatch.com 23 hrs ago 2 related
Drug stocks mixed, Medarex gains on drug news BOSTON (MarketWatch) -- Drug stocks were mixed in early trading Friday as shares of Medarex Inc. gained on news that it plans to present clinical data on its experimental melanoma treatment ipilimumab at major oncology conference later this month. The...
New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat...
redorbit.com 21 hrs ago 2 related
Posted on: Friday, 16 May 2008, 12:00 CDT Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008. Pfizer will hold two briefings for...